Thelansis

  Individuals with non-small cell lung cancer (NSCLC) who possess an epidermal growth factor receptor (EGFR) mutation constitute a distinct subgroup. The cancer's etiology, clinicopathological characteristics, prognosis, and treatment approaches differ from other NSCLC patients. EGFR mutations are present in 40%–60% of Southeast Asian patients and 10%–20% of Caucasian patients with lung adenocarcinomas. While most EGFR mutation-positive tumors are found in non-smokers or light smokers, this observation is not exclusive. The rising prevalence of non-smoking behavior has led to a higher incidence of EGFR mutations in female patients compared to male patients. In the Iressa Pan Asian Survival Study (IPASS) trial, which enrolled Asian non- or never-smoking lung adenocarcinoma patients, 80% of subjects were female, and 60% of tumors harbored EGFR mutations. Patients diagnosed with metastatic non-small cell lung cancer (NSCLC) carrying EGFR mutations are commonly treated with osimertin...